Últimas noticias sobre RAPT Therapeutics (NASDAQ:RAPT) Bolsa

RAPT Therapeutics

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

RAPT Therapeutics Inc

RAPT scraps zelnecirnon program, stock plunges 46% (update)

As previously reported, JPMorgan analyst Anupam Rama downgraded Rapt Therapeutics (RAPT) to Underweight from Neutral after the company announced th...

JPMorgan cuts Rapt Therapeutics to Underweight after zelnecirnon discontinued

Piper Sandler analyst Edward Tenthoff downgraded Rapt Therapeutics (RAPT) to Neutral from Overweight with a price target of $2, down from $8, after...

Rapt Therapeutics downgraded to Neutral from Overweight at Piper Sandler

In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on RAPT Therapeutics (RAPT – Research Report), with a price targ...

RAPT Therapeutics: Strategic Shift to Next-Gen Compounds Boosts Buy Rating Despite Program Termination

On July 16, 2024, the Company's board of directors approved a reduction of the Company's workforce to conserve cash resources. The workforce reduct...

Rapt Therapeutics reports Q3 EPS (47c), consensus (56c)

RAPT Therapeutics GAAP EPS of -$0.47 beats by $0.11

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Rapt Therapeutics Inc ( ($RAPT) ) has released its Q3 earnings. Here is a breakdown of the information Rapt Therapeutics Inc presented to its inves...

RAPT Therapeutics Reports Improved Q3 2024 Results

RAPT Therapeutics ( ($RAPT) ) has issued an announcement. RAPT Therapeutics has approved a repricing of underwater options for its employees, signi...

RAPT Therapeutics Reprices Underwater Employee Stock Options

AXSM

CTOR

CTXR

FULC

HRTX

MNOV

ONCY

PHAT

RAPT

RGEN

SNYNF

SYRS

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT

Press Releases

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

Earnings

RAPT Therapeutics Reports First Quarter 2024 Financial Results

News

Legal

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm

RAPT Therapeutics Reports Second Quarter 2024 Financial Results

Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

RAPT Therapeutics Reports Third Quarter 2024 Financial Results

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Clene

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Curis

CEL-SCI

Elevation Oncology

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroGen

Fresh2 Group Limited - American Depositary Shares

Fresh2 Group

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Kala Bio

Lantern Pharma

Lumos Pharma

NextCure

OKYO Pharma

OS Therapies

Passage Bio

Surrozen

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

Comments

RAPT Therapeutics

Noticias

Últimas noticias sobre RAPT Therapeutics (NASDAQ:RAPT) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL